[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.87. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
October 9, 2013

Sentinel Node Biopsy After Neoadjuvant ChemotherapyA New Standard for Patients With Axillary Metastases?

Author Affiliations
  • 1Department of Surgery, Breast Service, Memorial Sloan-Kettering Cancer Center, New York, New York
  • 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA. 2013;310(14):1449-1450. doi:10.1001/jama.2013.7844

Axillary lymph node dissection (ALND) reliably identifies lymph node metastases and results in a high rate of local cancer control, even in patients who initially present with node-postive disease. In patients initially presenting with node-negative breast cancer, ALND has been replaced by sentinel lymph node (SLN) biopsy. Sentinel lymph node biopsy involves injecting dye or tracer substances into the breast to selectively identify and remove the lymph nodes most likely to contain metastases. This is a much less morbid procedure than ALND.

First Page Preview View Large
First page PDF preview
First page PDF preview
×